Edition:
United States

Ardelyx Inc (ARDX.OQ)

ARDX.OQ on NASDAQ Stock Exchange Global Market

4.90USD
19 Apr 2018
Change (% chg)

-- (--)
Prev Close
$4.90
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
61,994
52-wk High
$14.05
52-wk Low
$4.05

Chart for

About

Ardelyx, Inc. is a clinical-stage biopharmaceutical company. The Company's therapeutics focuses on addressing cardiorenal and gastrointestinal (GI) diseases. It operates through the research, development and commercialization of biopharmaceutical products segment. The Company's products line includes cardiorenal portfolio and... (more)

Overall

Beta: 0.81
Market Cap(Mil.): $241.59
Shares Outstanding(Mil.): 47.60
Dividend: --
Yield (%): --

Financials

  ARDX.OQ Industry Sector
P/E (TTM): -- 200.91 33.50
EPS (TTM): -2.11 -- --
ROI: -59.85 -0.75 13.17
ROE: -60.12 -2.86 14.98

BRIEF-Knight Therapeutics Says ‍Will Have Exclusive Rights To Market And Sell Tenapanor In Canada​

* KNIGHT THERAPEUTICS - ‍LICENSE AGREEMENT WITH ARDELYX THAT PROVIDES KNIGHT WITH EXCLUSIVE RIGHTS TO COMMERCIALIZE TENAPANOR IN CANADA​

Mar 19 2018

BRIEF-Ardelyx Reports Qtrly Earnings Per Share $0.21

* ARDELYX REPORTS 2017 FINANCIAL RESULTS AND APPOINTS INDUSTRY VETERAN, JAN LUNDBERG, PH.D., TO BOARD OF DIRECTORS

Mar 14 2018

BRIEF-Ardelyx Says Co Had About $134 Million In Cash

* ARDELYX SAYS ON JAN 8, CO HAD ABOUT $134 MILLION IN CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS AS OF DEC 31, 2017 Source text: (http://bit.ly/2AETXHu) Further company coverage:

Jan 08 2018

BRIEF-Ardelyx Successfully Completes T3mpo-3 Safety Extension Study Of Tenapanor For Ibs-C

* ARDELYX SUCCESSFULLY COMPLETES T3MPO-3 SAFETY EXTENSION STUDY OF TENAPANOR FOR IBS-C

Jan 03 2018

BRIEF-Ardelyx announces license agreement with Shanghai Fosun Pharmaceutical Industrial Development Co for Tenapanor in China

* Ardelyx announces license agreement with Shanghai Fosun Pharmaceutical Industrial Development Company Limited for Tenapanor in China

Dec 11 2017

BRIEF-Ardelyx Inc says has decided to discontinue development of RDX7675 for treatment of hyperkalemia​​

* Ardelyx announces updated development path for its cardiorenal pipeline

Nov 21 2017

BRIEF-Ardelyx qtrly ‍net loss per common share $0.44​

* Ardelyx reports third quarter 2017 operating results and clinical progress

Nov 07 2017

BRIEF-Rock Springs Capital Management reports 5.02 pct passive stake in Ardelyx - SEC Filing

* Rock Springs Capital Management LP​ reports 5.02 percent passive stake in Ardelyx Inc as of Oct 23 - SEC filing Source text : (http://bit.ly/2gXpxsM) Further company coverage:

Nov 02 2017

Earnings vs. Estimates